Cardiac Arrhythmia Suppression Trial (CAST)

A Cardiac Arrhythmia Suppression Trial (CAST) is a Double-Blinded Clinical Trial that was carried out to determine whether drug treatment of asymptomatic ventricular arrhythmias in post-myocardial infarction patients reduces the occurrence of sudden cardiac death and mortality.

• Context:
  • ClinicalTrials.gov Identifier : NCT00000526.
• Example(s):
  • …
• Counter-Example(s):
  • Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo Trial,
  • A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants (SBP),
  • Shoulder Symptom Irritability Scale: A Single-Blinded Observational Study (SSIS).
• See: Clinical Trial, Blinded Clinical Trial, Premature Ventricular Contraction, Antiarrhythmic Agent, Myocardial Infarction, Mortality Rate, Paradigm Shift.

---

---

References

2021

• (Wikipedia, 2021) ⇒ https://en.wikipedia.org/wiki/Cardiac_Arrhythmia_Suppression_Trial Retrieved:2021-11-21.
  • The Cardiac Arrhythmia Suppression Trial (CAST) was a double-blind, randomized, controlled study designed to test the hypothesis that suppression of premature ventricular complexes (PVC) with class I antiarrhythmic agents after a myocardial infarction (MI) would reduce mortality. It was conducted between 1986 and 1989 and included over 1700 patients in 27 centres. The study found that the tested drugs increased mortality instead of lowering it as was expected. The publication of these results in 1991/92, in combination with large follow-up studies for drugs that had not been tested in CAST, led to a paradigm shift in the treatment of MI patients. Class I and III antiarrhythmics are now only used with extreme caution after MI, or they are contraindicated completely. Heart Rhythm Society Distinguished Scientist D. George Wyse was a member of the CAST trial's steering and executive committees.

---